[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Institute of Molecular and Translational Medicine, Czech Republic\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":283},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,86,120,142,168,194,222,243,264],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100530679","exhaled-breath-condensate-analysis-in-mechanically-ventilated-patients-100530679",false,"NCT06189924","Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients","Proteomic Analysis of Exhaled Breath Condensate in Mechanically Ventilated Intensive Care Patients","Inclusion Criteria:\n\nIntensive care setting Mechanical ventilation Ventilator\u002Fventilator circuit technically suitable for sampling of exhaled breath condensate\n\nExclusion Criteria:\n\nMechanical ventilation challenging to the extent that the insertion of the sampling kit into the ventilator circuit would substantially increase the risk for respiratory deterioration","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Mechanically ventilated intensive care patients will be sampled for a small amount of exhaled breath condensate from the ventilator circuit and for venous blood.\n\nProteomic analysis of the exhaled breath condensate will be performed using mass spectrometry and in the blood sample, corresponding changes in the DNA, RNA, proteins, and metabolites will be studied. Resulting profiles will be correlated with routinely monitored parameters in order to identify patterns corresponding to various pathologies in order to enable their early detection.",[24,25],"Acute Respiratory Failure","Critical Illness",[27,28,29,30,31,32,33],"exhaled breath condensate","proteomics","genomics","mechanical ventilation","acute respiratory failure","lung injury","intensive care","RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2026-03-01",{"date":42,"type":20},"2029-12-31",{"name":44,"class":45},"The Institute of Molecular and Translational Medicine, Czech Republic","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":4,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100410056","biomarkers-of-endometrial-receptivity-100410056","NCT04619524","Biomarkers of Endometrial Receptivity","Biomarkers of Endometrial Receptivity: A Prospective Multicenter Study on Proteomic Biomarkers of Endometrial Receptivity in Cervical Mucus ( PRO BIOMER - CM )","BIOMER","Inclusion Criteria - Arm A - stimulated cycle:\n\n* female aged less than 37 years (maximally 36y + 364d)\n* no smoker\n* normal menstrual cycles lasting between 25 to 35 days\n* had been infertile for less than five years\n* normal responder\n* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF\u002F intracytoplasmic sperm injection (ICSI) embryo transfer cycles and\u002For frozen-thawed embryo transfer cycles\n* sperm obtained through ejaculation\n* spermiogram more than 5 million sperm\u002FmL\n* BMI 19-29 kg\u002Fm2\n* follicle stimulating hormone (FSH) \\\u003C 10 IU\u002FL on the third day\n* basal antral follicle count of 5-15\n* undergoing the same routine gonadotrophin-releasing hormone agonist (GnRHa) long depot or gonadotrophin-releasing hormone antagonist (GnRH-ant.) protocol\n* informed consent\n\nExclusion Criteria - Arm A - stimulated cycle:\n\n* genetic disease\n* metabolic and\u002For endocrine disorders\n* polycystic ovary syndrome (defined by the Rotterdam criteria)\n* women with prior diagnosis of endometriosis or adenomyosis\n* previous gynecological\u002Fpelvic surgery except for salpingectomy\n* repeated spontaneous abortions (two or more)\n* previously less than 5 oocytes and\u002For serum anti-Mullerian hormone value \\\u003C 1.0 mIU\u002Fml or more than 20 oocytes, milli-International unit (mIU)\n* previous ovarian hyperstimulation syndrome (OHSS)\n* presence of any structural abnormality of the reproductive system\n* donor oocyte cycles\n* severe male factor infertility \\\u003C 5 million sperm\u002FmL\n* low response to stimulation\n* endometrium \\\u003C 8 mm at the day of human chorionic gonadotropin (hCG) or ET\n* number of retrieved oocytes 5 - 20\n* low fertilization capacity (rate of fertilization \\\u003C 20% and late ICSI following IVF fertilization failure)\n* OHSS\n* IVF cycle cancelled before ET\n* other than easy one high-quality blastocyst transfer (at least grade 3BB)\n\nInclusion criteria - Arm B - substituted cycle:\n\n* female aged less than 37 years (maximally 36y + 364d)\n* no smoker\n* normal menstrual cycles lasting between 25 to 35 days\n* had been infertile for less than five years\n* normal responder at stimulation\n* fewer than three failed cycles of assisted reproduction treatment, including fresh IVF\u002F intracytoplasmic sperm injection (ICSI) embryo transfer cycles and\u002For frozen-thawed embryo transfer cycles\n* sperm obtained through ejaculation\n* spermiogram more than 5 million sperm\u002FmL\n* BMI 19-29 kg\u002Fm2\n* FSH \\\u003C 10 IU\u002FL on the third day\n* undergoing the same routine estrogen\u002Fprogesterone substituted cycle\n* informed consent\n\nExclusion criteria - Arm B - substituted cycle:\n\n* genetic disease\n* metabolic and\u002For endocrine disorders such as diabetes, metabolic syndrome, and thyroid disorders\n* polycystic ovary syndrome (defined by the Rotterdam criteria), hyperprolactinaemia\n* women with prior diagnosis of endometriosis or adenomyosis\n* previous gynecological\u002Fpelvic surgery except for salpingectomy\n* repeated spontaneous abortions (two or more)\n* previously less than 5 oocytes and\u002For serum anti-Mullerian hormone value \\\u003C 0.5 mIU\u002Fml in the stimulated cycle\n* previous OHSS\n* presence of any structural abnormality of the reproductive system\n* severe male factor infertility \\\u003C 5 million sperm\u002FmL in the stimulated cycle\n* number of retrieved oocytes 5 - 20 in the stimulated cycle\n* low fertilization capacity (rate of fertilization \\\u003C 20% and late ICSI following IVF fertilization failure)\n* endometrium less than 8 mm at the day of thawing and transfer indication\n* thawed blastocyst cycle cancelled before ET\n* other than easy one best quality frozen\u002Fthawed blastocyst transfer (at least grade 3BB)","FEMALE","36 Years",{"count":58,"type":20},476,"INTERVENTIONAL",[61],"NA","Analysis of proteins from cervical mucus will be done in patients undergoing infertility treatment (fresh or frozen embryo transfer). Cervical mucus will be analysed for potential new biomarkers of endometrium receptivity. Comparison of the peptide spectrum will be done for the pregnant and not pregnant patients.",[64,65,66,67],"IVF","Infertility Treatment","Fertility Disorders","Embryo Transfer",[69,70,71,72,73,28,74,75,76],"cervix","mucus","endometrium","receptivity","biomarker","infertility","in-vitro","fertilisation","2026-03-19",{"date":79,"type":38},"2026-03-20",{"date":81,"type":38},"2018-05-01",{"date":83,"type":20},"2026-12-31",{"name":44,"class":45},3,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":55,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":59,"phases":99,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},"100379879","self-sampling-for-non-attenders-to-cervical-cancer-screening-100379879","NCT04226313","Self-sampling for Non-attenders to Cervical Cancer Screening","Cervical Cancer Prevention Using Self-sampling and Human Papillomavirus Detection","KOPRETINA","Inclusion Criteria:\n\n* Women with age 30-65 years; for arm A women \\> 65 years are allowed\n* Women live in the Czech Republic.\n* Women who have not participate in cervical cancer screening program in the Czech Republic for at least 3 years (Arm B and C).\n* Women with completed informed consent.\n* Women capable of self-sampling of cervicovaginal swab.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Women with no sexual intercourse experience.\n* Women after hysterectomy including cervix.",true,"30 Years","65 Years",{"count":98,"type":20},15000,[61],"The trial will evaluate whether self-sampling and human papillomavirus (HPV) testing may increase cervical cancer screening attendance among under-screened women in Czech Republic. Different ways of offering self-sampling device will be evaluated.",[102,103,104],"Cervical Cancer","Cervical Dysplasia","Human Papillomavirus Infection",[106,107,108,109,110,111],"human papillomavirus","HPV","self-sampling","cervicovaginal swab","cervical cancer screening","non-attendance",{"date":113,"type":38},"2026-03-23",{"date":115,"type":38},"2019-09-23",{"date":117,"type":20},"2026-12-01",{"name":44,"class":45},1,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":94,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":141,"locationsCount":119},"100374584","pulmonary-condensate-non-invasive-evaluation-of-pulmonary-involvement-in-asthma-and-cystic-fibrosis-100374584","NCT04157361","Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.","Pulmonary Condensate: A Promising Source of Proteomic Biomarkers for Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.","Inclusion Criteria:\n\n* Children\u002Fadults with moderate or IgE mediated asthma\n* Children\u002Fadults with cystic fibrosis\n* Healthy control children\u002Fadults without lung disorders\n\nExclusion Criteria:\n\n\\-",{"count":128,"type":20},450,"Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung injury, inflammation and infectious complications in chronic diseases like (CF) Cystic fibrosis or (AB) Bronchial asthma would be highly beneficial. Investigators propose to establish EBC \"breathprints\" revealing molecular signatures of pulmonary inflammation and specific respiratory bacterial infections of CF patients and AB. Investigators hypothesize that the analysis of EBC can reveal biomarkers specific for severity of the inflammation, and infection caused by opportunistic pathogens such as P. aeruginosa (PA). With these breath-prints, investigators also propose to establish correlations between respiratory microbiota using traditional methods and CF lung disease severity. Together, the studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of AB and monitoring of CF disease activity, treatment efficacy and PA or another opportunistic infections.",[131,132],"Bronchial Asthma","Pulmonary Cystic Fibrosis",[134,135,136],"Breath condensate","Bronchial asthma","Cystic Fibrosis",{"date":113,"type":38},{"date":139,"type":38},"2015-05-01",{"date":83,"type":20},{"name":44,"class":45},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":94,"sex":16,"minAge":148,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":59,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},"100595487","prevalence-of-human-papillomavirus-hpv-in-a-healthy-population-a-feasibility-study-of-oropharyngeal-cancer-screening-100595487","NCT07033091","Prevalence of Human Papillomavirus (HPV) in a Healthy Population: A Feasibility Study of Oropharyngeal Cancer Screening","Inclusion Criteria:\n\n* Participants aged 40 years or older at the time of enrollment.\n* Individuals who are capable of rinsing the oral cavity by gargling independently.\n* Signed informed consent for study participation, molecular-genetic testing, and personal data processing.\n\nExclusion Criteria:\n\n\\- Previously diagnosed head and neck cancer.","40 Years",{"count":150,"type":20},20000,[61],"This study defines the prevalence of oral infection with high-risk human papillomaviruses (hrHPV) in individuals over 40 years of age in the Czech Republic. It also establishes an effective methodology for oropharyngeal carcinoma screening and optimization of screening and testing procedures.",[154],"Oropharynx Cancer",[156,157,158],"Human Papillomavirus","HPV Infection","oropharyngeal cancer","2026-02-11",{"date":161,"type":38},"2026-02-13",{"date":163,"type":38},"2025-06-01",{"date":165,"type":20},"2031-03-30",{"name":44,"class":45},5,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":94,"sex":16,"minAge":17,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":119},"100395291","assesment-of-multiomics-profiles-in-health-and-disease-100395291","NCT04427163","Assesment of Multiomics Profiles in Health and Disease.","Assesment of Multiomics Profiles in Health and Disease - Corelation With the Disease Phenotype.","ENIGMA","Inclusion Criteria:\n\n* age 18 - 68 years\n* (for the first 1100 subjects):\n* healthy volunteers without genetically dependent disease and without such a disease in a family\n* healthy volunteer without the preliminary evidence of civilizational diseases such as hypertension, diabetes, autoimmune and tumor diseases or acute infectional diseases; clinically manifesting cardiovascular or pulmonary disability.\n* subject without permanent of long-term medication in the time of biological sampling.\n\nExclusion Criteria:\n\n* not complying with inclusion criteria","68 Years",{"count":178,"type":20},1100,"This study will determine reference genomic, transcriptomic, proteomic and metabolomic profiles in Czech population and will evaluate its correlation with the disease phenotype.",[181],"Genetic Predisposition to Disease",[183,184,185,186,187],"genomic profile","disease phenotype","proteomic profile","metabolomic profile","transcriptomic profile",{"date":161,"type":38},{"date":190,"type":38},"2018-09-01",{"date":192,"type":20},"2029-03-30",{"name":44,"class":45},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":94,"sex":16,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":59,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":85},"100517363","study-of-early-cancer-biomarkers-in-breath-condensate-in-population-of-individuals-with-high-risk-of-lung-cancer-undergoing-ldct-screening-100517363","NCT06016569","Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.","Prospective Validation Study of Early Cancer Biomarkers in Breath Condensate of Individuals With High-Risk of Lung Cancer Undergoing Low-Dose Computer Tomography Based Screening.","Inclusion Criteria:\n\n1. Consent to participate in a clinical trial.\n2. A clients within an age of 55-74 years.\n3. Current smoker or ex-smoker who has smoked at least 20 pack-years, provided that:\n\n   1. priority will be given to clients who have smoked at least 30 pack-years.\n   2. preference will be given to a former smoker who has not smoked for less than 15 years.\n\nExclusion Criteria:\n\n1. Previous diagnosis of lung cancer.\n2. Progressing malignant tumor on symptomatic treatment.\n3. Advanced dementia\n4. Chronic obstructive pulmonary disease or other inflammatory disease in the phase of acute exacerbation.","55 Years","74 Years",{"count":204,"type":20},3200,[61],"The trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate at any medical workplace and due to the relatively low financial cost of examination of the collected breath condensate could improve early diagnosis of lung cancer, differential diagnostics of lung nodules and thereby reduce both the unnecessary interventions and deaths from this type of cancer.",[208],"Lung Cancer",[208,210,211,212,213],"Breath Condensate","Biomarker","Screening","Early Cancer Detection","2026-02-10",{"date":216,"type":38},"2026-02-12",{"date":218,"type":38},"2023-06-01",{"date":220,"type":20},"2030-12",{"name":44,"class":45},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":242,"locationsCount":119},"100498769","role-of-liquid-biopsies-in-hpv-associated-cancer-treatment-monitoring-100498769","NCT05774561","Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring","Liquid Biopsies - a Possible Tool for Treatment Monitoring and Early Recurrence Detection in HPV-associated Diseases","Inclusion Criteria:\n\nWomen diagnosed with CC\u002FHSIL. Men and women diagnosed with OPC. Patients must agree with study enrollment and must sign study informed consent.\n\nExclusion Criteria:\n\nNo exclusion criteria are set.","99 Years",{"count":231,"type":20},480,"This trial will evaluate the possible benefits and the performance of liquid biopsies in HPV-associated cancer treatment monitoring. This study aims to find a combination of an adequately sensitive and specific sampling method and biomarkers for early risk stratification of disease recurrence.",[102,103,234,104],"Oropharyngeal Cancer",[106,107,236,109,237,158],"liquid biopsies","cervical cancer",{"date":216,"type":38},{"date":240,"type":38},"2022-06-01",{"date":117,"type":20},{"name":44,"class":45},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":119},"100601626","the-effect-of-multimodal-treatment-of-rectal-cancer-on-circulating-tumor-cells-a-prospective-observational-study-100601626","NCT07112937","The Effect of Multimodal Treatment of Rectal Cancer on Circulating Tumor Cells: A Prospective, Observational Study","Inclusion Criteria: rectal cancer -\n\nExclusion Criteria: no other cancer\n\n\\-",{"count":250,"type":20},150,"The prospective study will focus on patients undergoing multimodal treatment for rectal cancer. The main objective of the study will be to monitor changes in circulating tumor cells (CTCs) in the peripheral blood of patients during multimodal treatment. For each patient enrolled in the study, peripheral blood samples will be collected at specified time intervals to determine the presence and quantity of CTCs.\n\nThe CTCs levels will be compared among rectal cancer patients with neoadjuvant chemoradiotherapy and without neoadjuvant chemotherapy.",[253],"Rectal Cancer Patients",[255],"circulating tumor cells","2025-08-01",{"date":258,"type":38},"2025-08-08",{"date":260,"type":38},"2023-05-02",{"date":262,"type":20},"2027-12-31",{"name":44,"class":45},{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":94,"sex":16,"minAge":17,"maxAge":229,"enrollmentInfo":271,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":119},"100554625","non-invasive-brain-tumor-molecular-diagnostics-and-monitoring-100554625","NCT06501521","Non-invasive Brain Tumor Molecular Diagnostics and Monitoring","Non-invasive Brain Tumor Diagnosis Through Analysis of Proximal Fluids, Circulating Tumor Cells, and Biomolecules","Inclusion Criteria: Adult patients with brain tumors -\n\nExclusion Criteria: No other cancer; no inflammatory disease\n\n\\-",{"count":19,"type":20},"This prospective multicenter study aims to enroll GBM patients who will undergo repeated assessments (preoperatively and 3 months post-surgery) to detect circulating tumor cells and analyze the transcriptomic profiles of EVs in their blood. The prognostic and monitoring significance of these biomarkers to disease course (assessing treatment efficacy, resistance incidence, tumor progression) will be evaluated.\n\nConcurrently, proteomic profiles typical of GBM will be analyzed in blood and ocular secretion samples from GBM patients, patients with low-grade gliomas, and patients without brain tumors to identify and validate novel protein biomarkers suitable for disease monitoring. Additionally, this study proposes an innovative approach to monitor GBM patients by investigating the presence of GBM-specific nucleic acid fragments in urine.",[274],"Brain Tumor","2025-07-17",{"date":277,"type":38},"2025-07-18",{"date":279,"type":38},"2020-01-01",{"date":281,"type":20},"2030-12-31",{"name":44,"class":45},""]